- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02386358
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial (TRAENA)
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial
The purpose of this study is:
-to determine whether benznidazole (BZN) will be able to modify the natural evolution of chronic Chagas disease in adult patients by means of a randomized, double-blind clinical trial (RCT).
Also:
- -to validate therapeutic efficacy with new methods, such as recombinant antigen F29 of Trypanosoma cruzi visualized by conventional ELISA, in the context of the RCT compared with conventional serology (CS)
- -to develop the real-time polymerase chain-reaction (RT-PCR) to quantify the parasite load as an early therapeutic effect.
- to determine the potential of such serological and parasitological methods as predictors of therapeutic effect or failure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients and Methods. Patients selected to be enrolled were born in Chagas disease endemic areas of Argentina and bordering countries such as Bolivia and Paraguay, whose current residence is in urban non endemic areas of Argentina. They were sorted by clinical stage: stage 0, 1, 2 and 3 according to a modified Kuschnir classification.1 Briefly, Stage 0 corresponds to patients only with reactive serology for Chagas disease; stage 1, patients with reactive serology plus electrocardiographic abnormalities; stage 2, patients with the abovementioned characteristics plus dilatation of left ventricle by echocardiography, and stage 3, patients with the abovementioned characteristics, plus cardiac failure.
The follow-up was performed every 4 months during the first 2 years, every 6 months in the 3rd and 4th year, and annually from then on until the end of the study in 2012.
The safety of TRAENA was controlled at days 25 and 45 intra-treatment by means of laboratory tests and clinical evaluation, and at any time that an adverse event was apparent in patients.
Adherence to medication administration was verified by means of a booklet where the patient recorded the daily intake of medication and any physical abnormality that appeared during the time they were taking of medicine. Adherence was controlled by a surveillance and recovery system which consisted of telephone calls, telegrams, letters or home visits that was termed "active monitoring", which was immediately applied to the control visit when the patient did not attend the corresponding schedule control.
Telephone calls were the most useful tool to recover adherence to monitoring. Patients were assigned to BZN or Placebo treatment by an investigator independent from the research group. Prior to randomization, a pre randomization stratification was performed according to prognostic factors based on clinical stages of Chagas disease.
A database was designed to be used as the registry for the whole study. Demographic, epidemiologic, serologic, parasitological and clinical variables were used in its design, and were registered pre treatment, intra treatment and post treatment throughout the monitoring. Medical records were the primary documents for the registry, where all the variables were recorded manually. Based on the data, variables were registered on a daily basis and a random weekly check was conducted on the data against the medical records. Our Standard Operating Procedure was based on the following procedures: patient screening, selection and coding, sample collection, serum bank, DNA sample storage, monitoring systematization, surveillance systems to recover patients who had discontinued monitoring, etc.
In October 2011 the Base Data Monitoring Board for the last Interim Analysis, recommended an addendum modifying the secondary outcomes, adding simple and combined events. These events were characterized only by electrocardiographic abnormalities or associated to echocardiographic ones. These events were evaluated up April 2013.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 1063
- Instituto Nacional de Parasitología Dr Mario Fatala Chaben
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients living in urban areas
- Reactive to at least 2 for serological test performed in Fatala Chaben Institute (ELISA and IFI) ,
- Patients who agreed to be part of this protocol through informed consent form signed
Exclusion Criteria:
- Patients with chronic Chagas disease who have received prior treatment with benznidazole
- Other cardiomyopathies : idiopathic , alcoholic , peripartum myocarditis, secondary to coronary artery disease, valve disease, hypertension, restrictive, hypertrophic or congenital
- Chronic renal disease
- Bleeding disorders
- History of liver disease or current liver disease ,
- Any other severe clinical disease that decreases their life expectancy
- History of severe allergies
- Pregnant patients
- Patients who have not signed the informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Benznidazole
Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
|
Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
|
Placebo at a dose 5 m/Kg/day until 60 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular Mortality
Time Frame: Time to event: from date of randomization until the date of first documented progression or date of death from any cause up to 10 years of follow-up
|
Sudden death, unexpectedly in time and in its presentation,preceded by the abrupt loss of consciousness within a maximum of one hour of the onset of symptoms,when it happened during sleep or unexpectedly in a patient was stable until then.
Related Death, when presented in a patient with signs of progressive heart failure.Ischemic or Hemorrhagic Stroke
|
Time to event: from date of randomization until the date of first documented progression or date of death from any cause up to 10 years of follow-up
|
Development of heart failure
Time Frame: Time to event: from date of randomization until the date of first documented progression of heart failure up to 10 years of follow-up
|
Dyspnea is evaluated according to the classification of the New York Heart Association (NYHA),gallop rhythm, jugular venous distension, crackles in the lungs, edema or pleural effusion,hepatomegaly
|
Time to event: from date of randomization until the date of first documented progression of heart failure up to 10 years of follow-up
|
Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillator
Time Frame: Time to event: from date of randomization until the date of first documented progression up to 10 years of follow-up
|
Sustained ventricular tachycardia, atrioventricular block, trifascicular block, Atrial fibrillation
|
Time to event: from date of randomization until the date of first documented progression up to 10 years of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electrocardiographic endpoints. New development of permanent changes in the electrocardiographic
Time Frame: Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
|
Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Changes in clinical stage in chronic Chagas disease
Time Frame: Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Clinical progression
|
Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Enlargement of the left ventricle (LV) detected by echocardiography.
Time Frame: Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Clinical Progression
|
Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
New Heart Failure
Time Frame: Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Clinical Progression
|
Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Stroke
Time Frame: Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Clinical progression
|
Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up
|
Serological negativization
Time Frame: time to event: from the date of randomization to the date of the first documented serological negativization that persists until 10 years of follow-up
|
by ELISA F29 vs. conventional serology as a late indicator of efficacy or therapeutic failure.
|
time to event: from the date of randomization to the date of the first documented serological negativization that persists until 10 years of follow-up
|
Development and validation of RT-PCR
Time Frame: time to event: from the date of randomization to the date of the first documented no detectable RT-PCR that persists until 10 years of follow-up
|
Demonstration of RT-PCR as an early indicator of efficacy or therapeutic failure.
|
time to event: from the date of randomization to the date of the first documented no detectable RT-PCR that persists until 10 years of follow-up
|
Changes of the secondary objectives during RCT development. New single endpoints
Time Frame: Since October 2011 during 18 months
|
|
Since October 2011 during 18 months
|
Combined clinical endpoints:
Time Frame: Since October 2011 during 18 months
|
|
Since October 2011 during 18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Adellina R Riarte, MD, Chief of Clinical, Pathology and Treatment Department
Publications and helpful links
General Publications
- Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998 Oct;59(4):526-9. doi: 10.4269/ajtmh.1998.59.526.
- de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996 Nov 23;348(9039):1407-13. doi: 10.1016/s0140-6736(96)04128-1.
- Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994 Jan;127(1):151-62. doi: 10.1016/0002-8703(94)90521-5.
- Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006 May 16;144(10):724-34. doi: 10.7326/0003-4819-144-10-200605160-00006.
- Porcel BM, Bontempi EJ, Henriksson J, Rydaker M, Aslund L, Segura EL, Pettersson U, Ruiz AM. Trypanosoma rangeli and Trypanosoma cruzi: molecular characterization of genes encoding putative calcium-binding proteins, highly conserved in trypanosomatids. Exp Parasitol. 1996 Dec;84(3):387-99. doi: 10.1006/expr.1996.0127.
- Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. [Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy]. Arq Bras Cardiol. 1985 Oct;45(4):249-56. No abstract available. Spanish.
- Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004102. doi: 10.1002/14651858.CD004102.pub2.
- Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, Guyatt GH. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014 May 27;2014(5):CD003463. doi: 10.1002/14651858.CD003463.pub2.
- Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, Cura C, Auter F, Veron V, Qvarnstrom Y, Deborggraeve S, Hijar G, Zulantay I, Lucero RH, Velazquez E, Tellez T, Sanchez Leon Z, Galvao L, Nolder D, Monje Rumi M, Levi JE, Ramirez JD, Zorrilla P, Flores M, Jercic MI, Crisante G, Anez N, De Castro AM, Gonzalez CI, Acosta Viana K, Yachelini P, Torrico F, Robello C, Diosque P, Triana Chavez O, Aznar C, Russomando G, Buscher P, Assal A, Guhl F, Sosa Estani S, DaSilva A, Britto C, Luquetti A, Ladzins J. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis. 2011 Jan 11;5(1):e931. doi: 10.1371/journal.pntd.0000931.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRAENA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chagas Disease
-
Drugs for Neglected DiseasesLAT ResearchCompletedChagas' DiseaseArgentina
-
Evandro Chagas Institute of Clinical ResearchNot yet recruitingChronic Chagas DiseaseBrazil
-
BayerCompleted
-
Drugs for Neglected DiseasesCompletedChagas' Disease (Chronic) NosSpain
-
Drugs for Neglected DiseasesEisai Co., Ltd.UnknownChronic Chagas Disease, IndeterminateBolivia
-
Juan D. MayaRecruitingChronic Chagas DiseaseChile
-
Institut de Recherche pour le DeveloppementInstituto de Investigación Hospital Universitario La PazCompletedChagas' Disease (Chronic) With Other Organ InvolvementBolivia
-
Drugs for Neglected DiseasesUnknownChagas Disease | Trypanosomiasis, South American | South American Trypanosomiasis | Disease, ChagasBolivia
-
Evandro Chagas National Institute of Infectious...National Institute of Cardiology, Laranjeiras, BrazilCompletedChagas Cardiomyopathy | Chagas DiseaseBrazil
Clinical Trials on Benznidazole
-
Laboratorio Elea Phoenix S.A.Drugs for Neglected DiseasesRecruitingChagas DiseaseArgentina
-
Drugs for Neglected DiseasesUnknown
-
Tulane University School of Public Health and Tropical...University of California, San Diego; Institute for Clinical Effectiveness and...RecruitingChagas DiseaseUnited States, Argentina
-
Evandro Chagas Institute of Clinical ResearchNot yet recruitingChronic Chagas DiseaseBrazil
-
Drugs for Neglected DiseasesPhinC DevelopmentCompleted
-
Hospital de Niños R. Gutierrez de Buenos AiresThe Hospital for Sick Children; Thrasher Research Fund; Universidad Nacional... and other collaboratorsCompletedChagas DiseaseArgentina
-
Drugs for Neglected DiseasesEisai Co., Ltd.UnknownChronic Chagas Disease, IndeterminateBolivia
-
Drugs for Neglected DiseasesLAT ResearchCompletedChagas' DiseaseArgentina
-
Barcelona Centre for International Health ResearchCompleted
-
Barcelona Centre for International Health ResearchCompleted